Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer's disease.

Ageing research reviews·2026
Same author

Multi-objective hybrid GA-PSO optimized PI control for grid-connected PV-fed cascaded H-bridge multilevel inverter.

Scientific reports·2026
Same author

VEGF-A-Mediated Differentiation of Gingival Stem Cells to Endothelial Progenitor-Like Cells.

Tissue engineering. Part A·2026
Same author

Gedunin Impacts Pancreatic Cancer Stem Cells Through the Sonic Hedgehog Signaling Pathway.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target.

Cancer letters·2026
Same author

Midkine as a therapeutic node in NF1-driven neuro‑oncology: Biology, biomarkers, and translational strategies.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Neonatal expression of human FMRP isoform corrects cortical deficits and improves behavior in a mouse model of fragile X syndrome.

Molecular therapy. Nucleic acids·2026
Same journal

Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.

Molecular therapy. Nucleic acids·2026
Same journal

A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer.

Molecular therapy. Nucleic acids·2026
Same journal

Pyroptosis as a novel therapeutic target in glioblastoma multiforme: Mechanisms, molecular insights, and therapeutic potential.

Molecular therapy. Nucleic acids·2026
Same journal

Selection and validation of novel DNA aptamer panel co-specific to <i>Plasmodium falciparum</i> and <i>Plasmodium ovale</i> lactate dehydrogenase.

Molecular therapy. Nucleic acids·2026
Same journal

Therapeutic rescue of pathogenic asparaginyl-tRNA synthetase alleles.

Molecular therapy. Nucleic acids·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

6.5K

MicroRNAs and synaptic dysfunction in Parkinson's disease.

Morgan N Ogwo1, Bhupender Sharma1, Gunjan Goyal1

  • 1Center of Emphasis in Neuroscience, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.

Molecular Therapy. Nucleic Acids
|September 8, 2025
PubMed
Summary
This summary is machine-generated.

Synaptic microRNAs (miRNAs) are crucial for normal brain function and are implicated in Parkinson's disease (PD) pathology. Understanding their role may reveal new treatment strategies for this neurodegenerative condition.

Keywords:
Alpha-synucleinCerebral cortexDopaminergicMT: Non-coding RNAsMicroRNAsParkinson’s diseaseStriatumSubstantia nigraSynapseSynaptic plasticity

More Related Videos

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.2K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.5K

Related Experiment Videos

Last Updated: Jan 18, 2026

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

6.5K
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.2K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.5K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder characterized by synaptic dysfunction.
  • Synaptic health is essential for proper neurotransmission, and its impairment is central to PD pathogenesis.
  • MicroRNAs (miRNAs), particularly those within neuronal subcellular compartments, are increasingly recognized for their role in neurological diseases.

Purpose of the Study:

  • To review the role of synaptic microRNAs (miRNAs) in Parkinson's disease (PD).
  • To highlight miRNAs critical for normal synapse function and their involvement in PD pathology.
  • To explore the interplay between synaptic miRNAs and PD-associated synaptic dysfunction.

Main Methods:

  • Literature review focusing on synaptic miRNAs and their relevance to PD.
  • Analysis of current research on miRNA regulation of synaptic proteins.
  • Discussion of the impact of synaptic miRNAs on PD pathogenesis.

Main Results:

  • Synaptic miRNAs are vital regulators of synaptic activity and function.
  • Dysregulation of specific synaptic miRNAs is linked to PD pathology.
  • These miRNAs influence key synaptic proteins implicated in neurodegeneration.

Conclusions:

  • Synaptic miRNAs represent a promising area for understanding PD etiology.
  • Further investigation into synaptic miRNAs could unveil novel therapeutic targets for PD.
  • Targeting synaptic miRNAs may offer new avenues for treating Parkinson's disease.